(NASDAQ: MDXG) Mimedx Group's forecast annual revenue growth rate of 14.25% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 113.47%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.09%.
Mimedx Group's revenue in 2026 is $393,442,000.On average, 7 Wall Street analysts forecast MDXG's revenue for 2026 to be $62,854,556,280, with the lowest MDXG revenue forecast at $54,862,963,780, and the highest MDXG revenue forecast at $72,296,068,916. On average, 6 Wall Street analysts forecast MDXG's revenue for 2027 to be $70,868,364,103, with the lowest MDXG revenue forecast at $62,410,249,803, and the highest MDXG revenue forecast at $81,813,113,653.
In 2028, MDXG is forecast to generate $90,200,138,917 in revenue, with the lowest revenue forecast at $86,663,459,360 and the highest revenue forecast at $92,854,129,607.